Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A new clinical tool called the RE-ACT score, when combined with the existing HFA-ICOS risk model, significantly improves the ability to predict chemotherapy-related heart damage in cancer patients. The combined approach outperformed either score used alone, offering clinicians a smarter way to flag patients at risk for cardiotoxicity during anthracycline-based treatment.
Protecting the heart during cancer treatment just got a little more precise. Researchers have developed a novel clinical risk tool — the RE-ACT score — that, when layered on top of the existing HFA-ICOS risk model, significantly improves prediction of anthracycline-induced cardiotoxicity in chemotherapy patients. The findings, published in JACC: CardioOncology, suggest that combining a post-treatment assessment with baseline risk stratification is more powerful than relying on either approach alone.
The study drew on a derivation cohort of over 2,600 patients and a separate validation cohort of 819, all of whom received anthracycline-based chemotherapy. The RE-ACT score factors in baseline clinical variables, cumulative drug dose, and changes in heart function (LVEF) within the first month of treatment — making it a dynamic, post-treatment complement to the more complex, baseline-focused HFA-ICOS tool.
By the Numbers:
Why it matters: Cardiotoxicity is a serious and sometimes life-altering side effect of chemotherapy. A simple, validated post-treatment scoring tool could help oncologists and cardiologists identify high-risk patients earlier and tailor cardiac monitoring — potentially preventing heart failure down the line.
